Patients who develop a robust immune response to immune checkpoint inhibitors (ICIs) such as atezolizumab are at risk of poor clinical outcomes.

In a two-stage study, the researchers analysed patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab combination. In both stages, blood samples from a total of 132 patients...